Has Ivan Rivera Nazario received payments from drug or device companies?

Yes. Drug and device makers reported $7,232 in general payments to Ivan Rivera Nazario across 240 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ivan Rivera Nazario did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ivan Rivera Nazario come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ivan Rivera Nazario

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1124554449

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.

$7,232in general payments, 2019–2025

Across 240 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$1K
Medtronic$924
Novo Nordisk$581
Amgen$568
Eli Lilly Export S.A. Puerto Rico Branch$453
Sanofi-aventis U.S. LLC$408
plus $3K from 19 others

What the payments were for

Travel & lodging$6609%
Food & beverage$6,52290%
Gifts$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	29	$1,131
Medtronic	11	$924
Novo Nordisk	24	$581
Amgen(2 entities)	5	$568
Eli Lilly Export S.A. Puerto Rico Branch	21	$453
Sanofi-aventis U.S. LLC	16	$408
Dexcom, Inc.	20	$406
AstraZeneca	21	$391
Lilly USA, LLC	4	$344
Abbott	17	$322
PBG Puerto Rico LLC	15	$297
AbbVie	10	$230
Merck	8	$219
Bayer Puerto Rico Inc.	12	$219
Novartis	9	$212
E.r. Squibb & Sons, L.L.C.	2	$127
Corcept Therapeutics	4	$104
Chiesi USA, Inc.	2	$67
Radius Health, Inc.	2	$62
Rhythm Pharmaceuticals, Inc.	2	$46
Bayer	2	$32
Biohaven Pharmaceuticals, Inc.	1	$29
GSK	1	$24
Pfizer	1	$19
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,232 in reported general payments places this provider in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrulicityDulaglutide	22	$23,023
OzempicSemaglutide	22	$21,447
Synjardy XrEmpagliflozin/Metformin Hcl	22	$13,335
Trijardy XrEmpaglifloz/Linaglip/Metformin	19	$11,726
JardianceEmpagliflozin	13	$8,027
HumalogInsulin Lispro	14	$2,553
SynthroidLevothyroxine Sodium	35	$1,717
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	12	$1,178
Risedronate Sodium	12	$432
Atorvastatin Calcium	57	$431
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide	13	$130
Azithromycin	11	$89
Losartan Potassium	11	$88
Metformin Hcl	11	$83
Gabapentin	11	$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jardiance	$1,131	$33,08954 claims
Lilly USA, LLCTrulicity, Humalog	$344	$25,57636 claims
Novo NordiskOzempic	$581	$21,44722 claims
AbbVieSynthroid	$230	$1,71735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →